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Abstract 
Background: Serological markers for exposure to different Plasmodium species have recently been used in multiplex 
immunoassays based on the Luminex technology. However, interpretation of the assay results requires consideration 
of the half-life of specific antibodies against these markers. Therefore, the aim of the present study was to document 
the half-life of malaria specific serological makers, as well as assessing the sensitivity of these markers to pick up recent 
changes in malaria exposure.
Methods: A recently developed multiplex immunoassay was used to measure the intensity of antibody (Ab) 
responses against 19 different Plasmodium specific antigens, covering different human malaria parasites and two 
vector saliva antigens. Therefore, 8439 blood samples from five cross-sectional surveys in Ratanakiri, Cambodia, were 
analysed. These involve a random selection from two selected surveys, and an additional set of blood samples of indi-
viduals that were randomly re-sampled three, four or five times. A generalized estimating equation model and linear 
regression models were fitted on log transformed antibody intensity data.
Results: Results showed that most (17/21) Ab-responses are higher in PCR positive than PCR negative individu-
als. Furthermore, these antibody-responses follow the same upward trend within each age group. Estimation of the 
half-lives showed differences between serological markers that reflect short- (seasonal) and long-term (year round) 
transmission trends. Ab levels declined significantly together with a decrease of PCR prevalence in a group of malaria 
endemic villages.
Conclusion: For Plasmodium falciparum, antibodies against LSA3.RE, GLURP and Pf.GLURP.R2 are most likely to be 
a reflexion of recent (range from 6 to 8 months) exposure in the Mekong Subregion. PvEBP is the only Plasmodium 
vivax Ag responding reasonably well, in spite of an estimated Ab half-life of more than 1 year. The use of Ab intensity 
data rather dichotomizing the continuous Ab-titre data (positive vs negative) will lead to an improved approach for 
serological surveillance.
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Background
Despite a considerable decline, the malaria burden in the 
Greater Mekong Subregion is still high and has a major 
impact on public health, especially in some specific 
regions within countries [1]. With 68,000 malaria cases 
in 2013 and an annual parasite incidence rate of 4.6 per 
1000 persons, malaria is the main single-cause infec-
tious disease in Cambodia [2]. From 2000 to 2015, 
Cambodia has achieved a reduction of >75% in malaria 
case incidence [3], resulting in very low and heteroge-
neous malaria transmission clustered in hotspots and 
hotpops [2, 4, 5]. When aiming for malaria elimination, 
these focused areas of low malaria transmission pose 
Open Access
Malaria Journal
*Correspondence:  kkerkhof@itg.be; ldurnez@itg.be 
1 Department of Biomedical Sciences, Institute of Tropical Medicine, 
Antwerp, Belgium
Full list of author information is available at the end of the article
Page 2 of 18Kerkhof et al. Malar J  (2016) 15:529 
considerable challenges for epidemiological surveillance 
and evaluation of control and elimination measures [6].
In malaria elimination areas, detection and surveillance 
of persisting malaria transmission is key for focussing 
interventions [7]. Traditional techniques for determin-
ing malaria transmission intensity include entomological 
inoculation rates (EIR) and parasite prevalence (PP) esti-
mates [8]. However, in low transmission areas, the EIR 
and PP lack sensitivity, due to very low numbers of para-
site-positive samples, both in mosquitoes and humans [9, 
10].
Alternatively, serology is believed to be more informa-
tive in obtaining epidemiological information in malaria 
control programmes. In particular, serological mark-
ers can be used as a proxy for Plasmodium transmission 
intensity in low endemic areas [11] where parasite car-
riage is reduced and vector populations persevere [12]. 
More specifically this corresponds to the measurement 
of the force of infection (FOI), reflecting a rate at which 
susceptible individuals acquire an infection per year in a 
given area [9]. Where the EIR and PP mainly focus on the 
presence or absence of the infection [11] serology focuses 
on antibodies (Abs) that remain in the blood longer than 
the parasite. This is profitable in measuring host-parasite 
contact, and may provide information on recent or past 
malaria exposure, but only in case the half-lives of the 
Abs are known [11, 13, 14].
From an immunological point of view, partial protec-
tive immunity to malaria is built up after recurrent infec-
tions, typically over a period of several years of exposure. 
Hence, different types of memory are expected based on 
the frequency of short- (several months) and long-lived 
plasma cells (years) [15]. In areas of seasonal malaria 
transmission, it is assumed that short-lived plasma cells 
appear early in life and long-lived plasma cells later on 
[16], which can be used to understand the measurements 
of Ab half-lives [16]. It is important to take into account 
the different parasite life stages (skin, liver and early 
blood stages) as well [17]. Producing Abs against sporo-
zoites or merozoites is challenging, due to the short time 
that sporozoites need to reach and penetrate liver cells, 
and for merozoites to reinvade erythrocytes. Strong Ab-
responses are expressed against early blood stage Ags, 
which can be more useful in estimating cumulative expo-
sure [12, 17]. Even though it is difficult to determine the 
half-life of Abs, some studies have already studied the Ab 
persistence [18–20].
The aim of the current study is to document the half-
life of IgG-Abs against 21 Ags from specific malaria 
parasites (Plasmodium falciparum, Plasmodium vivax, 
Plasmodium malariae) and saliva of vectors as well as 
assessing the sensitivity of the markers to pick up recent 
changes in malaria exposure. Methods to estimate the 
half-life of serological markers are still in its infancy, 
therefore, to reach this goal, three different approaches 
[13, 21] were applied directly on continuous Ab intensity 
values (Fig.  1) instead of using (arbitrary) thresholds to 
distinguish positives from negatives [22]. First, a com-
parison of the Ab-intensity between PCR-positive and 
PCR-negative samples was performed. Secondly, the half-
life of the serological markers was documented by ana-
lysing sequential samples. Thirdly, the Ab-responses were 
examined in relation to the PCR endemicity. As there is 
no golden standard, the use of multiple approaches will 
improve the robustness of the results. As such, serologi-
cal markers that perform best for all three approaches 
are considered to be most promising in reflecting recent 
exposure.
Methods
Malaria transmission patterns in the study area
Ratanakiri is the highest malaria endemic province of 
Cambodia. Malaria transmission occurs during the 
rainy season, between April/May and October/Novem-
ber. Over the years a major decline in malaria transmis-
sion had been observed in this province: In 2000, the 
recorded annual parasite incidence in Ratanakiri was 
11/1000 inhabitants, whereas [23, 24] in 2012 an average 
incidence of 3.1/1000 inhabitants were reported [4]. The 
observed decline is attributed to the performance of the 
National Malaria Control Programme (high long-lasting 
insecticidal net coverage and improved case manage-
ment) but also to environmental changes (deforestation) 
impacting the main vector (Anopheles dirus) [2].
Samples
Serum samples used for this study were collected dur-
ing the cluster randomized trial organized within the 
MalaResT project, NCT01663831, that aimed to evalu-
ate the use of topical repellents as added control measure 
to long-lasting insecticidal nets for prevention of malaria 
[4, 5] in Ratanakiri province, Cambodia. The project took 
place in the 98 most endemic clusters in Ratanakiri (88 
single villages and 25 neighbouring villages grouped into 
10 clusters) [25]. These 98 clusters were split into two 
arms, a control (long-lasting insecticidal nets) and an 
intervention arm (long-lasting insecticidal nets and the 
topical repellent picaridin). During 2 consecutive years 
(2012/2013) individuals were sampled by collecting two 
drops of blood on filter paper through a finger prick. To 
obtain baseline information on malaria prevalence at clus-
ter level, the first survey (a pre-trial study) was conducted 
February 2012 (PCR prevalence 6.34%) [4, 25]. Four addi-
tional cross-sectional surveys were performed at the start 
of the rainy season in April/May (surveys 1, 2012 and 3, 
2013) and 6  month later in October/November (surveys 
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Fig. 1 Overview of the study, indicating the antigens used in each step
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2, 2012 and 4, 2013) with a PCR prevalence between 3 and 
4% [25]. No differences in PCR prevalence were observed 
between the two study arms. PCR positive persons 
received a 3-day treatment with dihydroartemisinin plus 
piperaquine immediately following the national treatment 
guidelines [5, 25]. The immunoassay was performed on 
a total of 8438 out of 26,929 blood spot samples. Of this 
total, 6502 samples were randomly selected from survey 2 
(3264 out of 4996 samples) and survey 4 (3238 out of 5431 
samples). In addition, a total of 452 samples from the pre-
trial and all four trial surveys were analysed as they were 
PCR positive for Plasmodium parasites. Furthermore, all 
samples of individuals that were randomly re-sampled 
three (430 individuals), four (36 individuals) or five times 
(10 individuals) during the entire MalaResT project were 
also included (Fig. 1). For the immunoassay blood spot fil-
ter papers were prepared by punching one disc of 6 mm 
(diameter), and eluted overnight in 160  μL of PBS-TBN 
[PBS-1% BSA-0.15% Tween, pH 7.4, Sigma-Aldrich (dilu-
tion 1:40)]. Just before use in the immunoassay, the eluted 
samples were diluted to 1:200 in PBS-CR, as previously 
described [26].
Antigens
The selection of Ags was based on their availability and 
tested in a previous study that focused on the implemen-
tation of the multiplex bead-based immunoassay [26]. 
The current assay includes eleven Plasmodium specific 
peptides, and eight Plasmodium specific recombinant 
proteins. These 19 Ags cover most stages of the life cycle 
of the parasite in the host (Table  1; Fig.  1). In addition, 
two peptides specific for the Anopheles gambiae saliva 
protein gSG6 (salivary gland 6) were included. All pep-
tides were chemically synthesized with an added N-ter-
minal cysteine residue and BSA (bovine serum albumin, 
Sigma-Aldrich, St. Louis, USA) [27] by GeneCust Europe 
(Dudelange, Luxembourg). The recombinant proteins 
were produced as described in Table 1.
Covalent coupling of antigens to the beads/microspheres
Each Ag was covalently coupled at a concentration of 
4  μg  Ag/106 beads to 35  ×  106 paramagnetic beads/
beadset (MagPlex microspheres, Luminex Corp., Aus-
tin, TX, USA) [26]. BSA (Sigma-Aldrich, St Louis, USA) 
was coupled to an additional set of beads to serve as a 
background control. All beads and the BSA were mixed 
to prepare a microsphere working mixture. This mix-
ture was then aliquoted and stored at 4 °C in portions of 
500 μl per tube [26].
Bead‑based immunoassay
The immunoassay was conducted as previously described 
[26]. First, a 500  μl aliquot of the microsphere working 
mixture was diluted to a final volume of 5000 μl (1:10) with 
a concentration of 1000 beads/Ag/well. From this micro-
sphere working mixture 25  μl was added in each well of 
a 96-well plate followed by 50 μl of diluted serum sample 
(1:200) [26]. As a control for the immunoassay, a pool of 
negative sera (non-exposed European sera) was added to 
each plate in duplicate at a dilution of 1:100 in PBS-CR. A 
pool of positive sera containing sera from four individuals 
tested positive for P. falciparum and two for P. vivax [26] 
was added to each plate in duplicate at dilutions 1:100, 
1:400 and 1:1600. For the washing steps PBS-TBN was 
used, and 100 μl/well of secondary Ab (R-phycoerythrin+-
conjugated AffiniPure F(ab’)2 fragment of goat anti-human 
IgG, Jackson Immuno Research Laboratories) at a dilu-
tion of 1:500 was added [26]. All plates were analysed in 
a random order to minimize a bias. In a final step, beads 
were resuspended in 100  μl of 5% PBS-BSA, pH 7.4. In 
total, 216 plates were analysed and read by the MAGPIX® 
system with a minimum amount of 400 beads per spectral 
address. Results were represented as the median fluores-
cent intensity (MFI—Additional file 1) [26].
Statistical analysis
A scheme of the data analysis can be found in Fig. 1. Raw 
data were processed and analysed in R version 3.1.0. [28]. 
To assure the validity of the results of each plate a qual-
ity control was performed. Results were corrected for 
background signal by substracting the signal obtained 
with BSA-coupled beads (MFIBSA) from the median 
value of the Ag-coupled beads (MFIAg), defined by 
∆MFI = MFIAg−MFIBSA [26]. The MFI-values of the high 
positive control pool samples and the percentage positiv-
ity (�MFILow positive control(Ag1)
�MFIHigh positive control(Ag1)
 × 100%) from the low posi-
tive control (50% value of the high positive control) pool 
samples were plotted in Levey Jenning Charts. The high 
positive (100% value) is determined per Ag and based on 
the 1:100, 1:1400 and 1:1600 serum dilutions. The plates 
with samples outside the range of −2SD and +2SD were 
rejected and repeated (Additional file 2) [26].
Further differences between duplicate samples were 
explored using a quantile regression on an MA-plot using 
R package ‘OutlierD’ [29]. M is the difference between the 
duplicate samples and A is the average of the duplicate 
samples [30, 31]. Samples that fell outside the lower 25% 
and upper 25% quantiles of this MA-plot were rejected 
(Additional file 4). Hereafter, the means of the duplicates 
were calculated per sample of each Ag. All analyses were 
carried out on the natural logarithm (ln) of the raw MFI 
in accordance with Helb et al. [13].
As age influences Ab-responses [11, 32], age categories 
were created based on the work of Kusi et al. [8]. To explore 
whether the age categories defined were al biologically 
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relevant in the study region, the (ln) MFI values were plot-
ted against age (Additional file 5). Moreover, to account for 
multiple comparisons Bonferroni corrections were applied 
to each of the following approaches [33, 34].
Towards selecting markers that pick up contact with 
the parasite (recent of not recent), ln(MFI) values of PCR 
positive and PCR negative samples were compared per 
Plasmodium species. Generalized estimating equation 
(GEE) models were used (geeglm function in the R pack-
age ‘geepack’ [35–37]), taking into account the within-
cluster correlations that might exist due to the sampling 
design (village level clustering) [38]. The model also takes 
Table 1 Overview of the antigens (peptides and recombinant proteins) used in this study
Ags are organized according to the Plasmodium species and the life-cycle stages in the human host
Antigens Sequence (N‑terminal 
to C‑terminal)
g/mol Life‑cycle stages Plasmodium  
species





2257.67 Sporozoite P. falciparum Peptide [27]
Pf13 C-terminal His-tag pro-
duced in E. coli
Sporozoite P. falciparum Recombinant protein [69, 70]
STARP.R STDNNNTKTISTDNNNTKTIC 2299.42 Sporozoite and liver stage P. falciparum Peptide [27, 71]
SALSA2 NGKDDVKEEKKTNEKKDDG-
KTDKVQEKVLEKSPKC
4019.52 Sporozoite and liver stage P. falciparum Peptide [27, 71]






5297.97 Liver stage P. falciparum Peptide [27, 72, 73]
LSA1.J ERRAKEKLQEQQS-
DLEQRKADTKKC
3046.43 Liver stage P. falciparum Peptide [27, 71, 73]
LSA3.RE VESVAPSVEESVAPSVEESVAE-
NVEESVC
2991.20 Liver stage P. falciparum Peptide [27, 71]
Pf.MSP1.19 Glutathione S-transferase 
(GST) fusion protein. 
C-terminal expressed in 
E. coli
Merozoite P. falciparum Recombinant protein [38, 40]
GLURP EDKNEKGQHEIVEVEEILC 2241.47 Trophozoite P. falciparum Peptide [27, 71, 74]
Pf.GLURP.R2 C-terminal produced in 
E.coli








2905.95 Sporozoite P. vivax Peptide [71, 76, 77]
PvCSP (chimera) Soluble His-tag protein 
expressed in a wheat-
germ cell free expression 
system
Sporozoite P. vivax Recombinant protein [76, 77]
PvAMA1 Merozoite P. vivax Recombinant protein [78, 79]
PvEBP Merozoite P. vivax Recombinant protein [80, 81]
PvDBP Merozoite P. vivax Recombinant protein [81]
Pv.MSP1.19 C-terminal produced in the 
baculovirus expression 
system
Merozoite P. vivax Recombinant protein [38, 40, 48]
PmCSP GNAAGNAAGNDAGNAA-
GNAAGNAAGNAAGNAAC
2358.37 Sporozoite P. malariae Peptide [71]
SALIV1 EKVWVDRDNVYCGHLDC-
TRVATFC
2830.22 Salivary gland proteins An gambiae Peptide [27, 82]
SALIV2 ATFKGERFCTLCDTRHFCECK-
ETREPLC
3324.84 Salivary gland proteins An gambiae Peptide [27, 82]
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into account PCR positivity and age as factors allowing 
estimation of “population-averaged” effects [38, 39]. Dif-
ferent GEE-models were compared through ANOVA (a P 
value < 0.05 was considered significant) tests to select the 
most appropriate model per Ag: (1) a null model (inter-
cept-only model), (2) a model with only PCR prevalence 
as a dependent variable, (3) a model with only age groups 
as a dependent variable, (4) a model with PCR prevalence 
and age groups as dependent variables (without interac-
tion and (5) with interaction).
To estimate the half-life of the Abs after effective treat-
ment of malaria, the presence of Abs in the same individ-
uals (642 persons) followed up over time (±600 days) was 
examined [40]. Therefore, only individuals that were PCR 
positive in at least one survey were selected and the time 
of PCR positivity (and effective treatment) was taken as 
time point zero. This allows assessing the dynamics of the 
Abs against different Ags. Three linear models were com-
pared per Ag through ANOVA tests: (1) a model with 
time since infection as dependent variable, (2) a model 
with time since infection and age groups as dependent 
variable (without interaction and (3) with interaction). 
Based on the slope (=λ) of the selected model, the half-




[8, 41]. The 95% confidence intervals (95% CI) were esti-
mated using the ‘confint’ function in R [28]. This analysis 
was performed on the systematically parasite negative 
individuals as well.
For determining the association between Ab-levels at 
population level and PCR-prevalence of asymptomatic 
Plasmodium infections, the ln(MFI) values were plotted 
against PCR prevalence at cluster level. Therefore, forest 
plots (multiplot function in the R package ‘grid’ [28] and 
forest plot function in R package ‘ggplot2’ [42]) were cre-
ated on the cluster prevalence data from survey 2 and 4 
per Plasmodium species. For P. falciparum and P. vivax 
this was performed on mono infections and for the An. 
gambiae saliva proteins on all infections (regardless of 
Plasmodium species). Each cluster was examined twice, 
once for survey 2 and once for survey 4. Then, the preva-
lence data were ordered from low to high prevalence 
(Additional file  7) and split into different groups repre-
senting low, medium and high prevalence (cut2 func-
tion in R package ‘Hmisc’ [43]). For each species, groups 
of clusters that showed an overlap between medium and 
high-level PCR prevalence were excluded, allowing a 
clear distinction between three groups (high-, medium- 
and low-level PCR prevalence). Thereafter, ln(MFI) val-
ues were age-adjusted as differences in Ab-levels can 
be found between different age categories. Finally, lin-
ear models taking into account cluster within survey as 
random effect (lmer function in R package ‘lme4’ [44]) 
were compared through ANOVA tests: (1) a null model 
(intercept-only model), (2) a model with PCR prevalence 
as a dependent variable, (3) a model with PCR prevalence 
and age as dependent variables (without interaction and 
(4) with interaction). The Incidence Rate Ratio (IRR) is 
corresponding to a ratio of Ab-levels estimated directly 
with the R-software.
Results
Although PmCSP was included in the battery of Ags, the 
results for PmCSP are not shown as the MFI signal (mean 
MFI < 600) did not surpass the background signal for the 
BSA.
Quality control
A total of 8654 field blood samples were analysed distrib-
uted over 108 96-well plates. Each plate was analysed in 
duplicate. After quality control, out of the 216 plates 30 
plates were repeated (Additional file 2). The control sam-
ples fell within the linear range of the assay (Additional 
file  3). Samples were checked for uniformity across the 
measuring range of the assay by looking at the between 
plate variation of the samples (>96%). Thereafter, based 
on the quantile regression (Additional file 4), between 10 
and 17% of the duplicate samples depending on the Ag 
were not consistent with each other and were excluded 
from the dataset. When determining the age categories, 
samples from individuals above 50 years were excluded, 
due to large variations in MFI values and a limited num-
ber of available samples (Additional file 5).
Comparison of MFI values between PCR positive and PCR 
negative samples
For 17 out of 20 Ags, the Ab levels were higher in PCR 
positive as compared to PCR negative blood sam-
ples (P  <  0.0025, Bonferroni correction for 20 different 
tests) (Fig.  2). However, Ags PvVK210.CSP (P =  0.842), 
PvVK247.CSP (P = 0.557) and PvCSP (P = 0.009) did not 
show significant differences between the Ab levels within 
the age groups. As such, these three Ags were omitted 
from the figure. For 12 out of 20 Ags (CSP, Pf13, SALSA2, 
SR11.1, LSA1.J, LSA3.RE, Pf.MSP1.19, PvAMA1, PvDBP, 
Pv.MSP1.19, SALIV1 and SALIV2) there w0as no inter-
action between PCR status and age group, meaning that 
PCR-positive persons have significantly higher Ab levels 
for 12 Ags than PCR-negative persons (Fig. 2), within all 
age groups (model 4, P < 0.0038).
For five other Ags the model that includes the inter-
action between PCR-positivity and the age groups was 
selected as the best model, showing that there is a sig-
nificant difference in MFI values between PCR positive 
and PCR negative samples (P < 0.01, Bonferroni correc-
tion for five tests), but that the magnitude of the differ-
ence depends on the age group. These Ags can be divided 
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Fig. 2 Antibody responses to Plasmodium antigens, stratified by age and the presence or absence of malaria infection. Individuals were divided 
into three age groups (1–5, 6–15 and 16–50) to explore the relation with age. Previous obtained PCR results [4, 5] were used to determine the pres-
ence and absence of the Plasmodium infection. Boxplots represent the medians, interquartile ranges and error bars show 95% confidence intervals. 
Circles represent outlier values. Generalized estimating equation (GEE) models were conducted taking into account Cluster as a random effect. Ags 
with non-significant results were not included in the figure
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into two different groups. First PvEBP shows a significant 
difference (P < 0.01) between MFI values of PCR positive 
and PCR negative persons only in the younger age groups 
(2–5 and 6–15 years old), whereas for STARP.R, LSA1.41, 
GLURP and Pf.GLURP.R2 the differences in MFI values 
between PCR-positive and PCR-negative persons are 
significant (P < 0.01) in the older age groups (6–15 and 
16–50 years old) only.
Ab‑responses decline with days since infection, depending 
on age and serological marker
There is a lot of variation between the estimated half-life 
per serological marker, suggesting that it is possible to 
distinguish short (seasonal) and long-term (year round) 
transmission trends. The model with time since infection 
and age groups as dependent variables (without interac-
tion) was selected as the best model for all 20 Ags, sug-
gesting that age does not have an effect on the slope of 
the Ab decay, although the Ab titres at time point zero 
differ between age groups (Figs. 3, 4). For nine antigens 
(CSP, STARP.R, SALSA2, SR11.1, LSA1.J, LSA3.RE, 
GLURP, Pf.GLURP.R2 and PvEBP) a pronounced decay 
of the Ab titres was observed (Fig. 3). When comparing 
these graphs with the group of individuals being system-
atically negative, Ags LSA3.RE, GLURP and Pf.GLURP.
R2 showed a much steeper decay in the group of individ-
uals being PCR positive one time. Besides, the graphs of 
the PCR positive seems to flow into the negative groups, 
showing a difference between the intercept of >2. This 
outcome suggests that these Ags are most promising for 
reflecting short-term patterns in malaria transmission. 
Estimated half-lives, ranging between 6 months (176 [CI 
119–338] days) for Pf.GLURP.R2 and more than 2 years 
for some P. vivax Ags, clearly depend on the serologi-
cal marker used (Fig.  5; Additional file  6). Abs against 
five Ags (Pf.GLURP.R2, SR11.1, LSA3.RE, GLURP and 
Pf.MSP1.19) show estimated half-life values shorter 
than approximately 7.5  months, with estimated half-
lives ranging from 6  months (176 [CI 119–338] days) 
until ~7.5  months (225 [CI 171–329] days). Estimated 
half-lives of Abs against STARP.R, Pf13, CSP, SALSA2 
and SALIV.2 range between ~8.5 months (263 [CI 159–
768] days) until ~1 year (373 [CI 284–546] days) and of 
Abs against LSA1.J, SALIV.1, LSA1.41, PvAMA1 and 
PvMSP1.19 from ~1.1  year (402 [CI 203–16,035] days) 
until ~1.6 year (597 [CI 350–2020] days). Remaining Abs 
show an estimated half-life of more than 2 years.
For this analysis for some Ags (CSP, STARP.R, SALSA2, 
SR11.1, LSA1.41 and Pf.MSP1.19) samples from young 
children (2–5 years) were not included, due to a limited 
amount of samples available. For the same reason the age 
group of 16–50 years old was excluded for LSA3.RE.
Intensity of the Ab‑responses decreased together with the 
malaria exposure
To test whether Abs pick up recent malaria exposure in 
a population, the relation between Ab-titres (ln(MFI)) 
and the PCR prevalence of malaria in the province of 
Ratanakiri was explored. Therefore, the cluster PCR 
prevalence data from survey 2 and 4 was divided into dif-
ferent groups (forest plots: Additional file 7). In the forest 
plot, clusters with PCR prevalence between 3.5 and 7% 
were situated in the overlap between the medium- and 
high-level PCR prevalence and were not considered for 
present analysis, reflecting only those exhibiting high 
(7–  >10%), medium (1–3.5%), and low (0–  <1%) PCR-
prevalence levels (Table 2). For Ags SALIV.1 and SALIV.2 
all Plasmodium data (mono and mixed infections) were 
used, whereas the P. falciparum and P. vivax Ags were 
analysed species specific (only mono infections).
For all 20 Ags, the model with PCR prevalence levels 
and age groups as dependent variables (without interac-
tion) was selected. This model shows that when the PCR 
prevalence in groups of villages becomes lower, MFI lev-
els also decrease (P  <  0.0025; Additional file  8), within 
all age groups. Moreover, with decreasing endemicity 
Ab responses to the Ags presented in Fig. 6 show a more 
marked decline (drop in IRR between PCR prevalence 
level in respect to the reference group), as well as an 
increase in IRR with age. Biggest decline in IRR between 
PCR prevalence level was seen for Ags LSA3.RE, GLURP, 
Pf.GLURP.R2 and PvEBP, whereas the highest increase in 
IRR with respect to age was seen for Ags CSP, LSA1.41, 
LSA3.RE, GLURP, Pf.GLURP.R2 and PvEBP compared to 
the other Ags (Fig. 6).
Selection of informative antigens for recent infection are 
based on three criteria
To determine which Ags best reflect recent malaria expo-
sure (seasonal) the following three criteria were used: (1) 
(See figure on previous page.) 
Fig. 3 Plasmodium falciparum Ab profiles in relation to time since last infection compared to the systematically negative individuals. Each serologi-
cal marker is analysed for Plasmodium falciparum infections and three age groups (1–5, 6–15 and 16–50). Samples collected through longitudinal 
follow-up were aligned, starting with putting the malaria episode detected by PCR at time point zero. Points represent the different samples in 
which a linear regression is drawn through with the 95% confidence intervals. These outcomes were then compared to the group of individuals 
being systematically negative over time, to see if the Ab-levels follow a similar or different decay over time between the parasite positive and nega-
tive individuals
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the outcome of the estimated Ab-responses based on the 
differences in ln(MFI) between PCR positive and PCR 
negative individuals, (2) the assessed half-lives and (3) 
the estimated Ab-responses in relation to high-, medium- 
and low levels of Plasmodium exposure (Table 3). Based 
on these criteria the Ags that are most likely to reflect 
recent malaria exposure to P. falciparum are LSA3.RE, 
GLURP and Pf.GLURP.R2. Among the seven Ags tested 
for P. vivax, PvEBP is the most prominent choice.
Discussion
Several research groups recently developed multiplex 
serological assays for the detection of Abs against Plas-
modium Ags [27, 38, 45–48]. Previous studies combin-
ing short- and long-lived markers for Plasmodium have 
generated knowledge about past and recent changes in 
malaria transmission within communities [13, 40, 49]. 
This has led to an increasing interest in the use of serol-
ogy in acquiring epidemiological information that can 
be implemented in malaria control programmes [9, 13, 
40, 49–55]. At this point, the majority of the studies and 
elimination programmes have focused in first instance on 
P. falciparum [13, 27, 38, 45, 46, 52, 56], which is easier 
to eliminate than P. vivax due to possible relapses in the 
latter one [57]. However, in contrast to other studies the 
current study was carried out in Southeast Asia (Cam-
bodia) where all human malaria parasites are co-occur-
ring [26, 58] and in which occupational and behavioural 
factors define the risk for malaria exposure [59–61]. As 
such, adolescents and mainly adults performing planta-
tion work and forest activities are the main risk groups 
for malaria infection [59–62]. In this setting, insights into 
malaria transmission will be greatly enhanced by analys-
ing age-adjusted Ab-responses directed against Plasmo-
dium parasites including P. vivax. However, in this study 
age did not show any interactions on the outcomes.
The present study is to our knowledge the first study 
in Southeast Asia that uses multiplex serological meas-
urements to document the half-life of IgG-Abs. Previ-
ous studies declare that Ab-levels follow a predictable 
pattern, in which every few months the Ab-level drops 
by half in the absence of re-infection [18, 41, 63]. To 
estimate this drop and apply those values in assessing 
the force of infection (FOI) in a study population, most 
researchers use a reversible catalytic conversion model 
[6, 40, 49, 51] on cross-sectional data. Such model is a 
simplification of a complex immunological process in 
which serological responses are converted to binary out-
comes (seropositive or seronegative) through a thresh-
old model [52]. Hence, these binary outcomes may 
lead to a loss of information due to the high range of 
MFI values within the seropositive group, and misclas-
sification might occur because of subtle changes in the 
Ab-responses over time due to other infections or small 
laboratory variations [9]. Another limitation is that this 
model assumes a fixed sero-reversion rate, independ-
ent of age and transmission rate [51]. Therefore, some 
studies elaborated this model by comparing longitu-
dinal- and cross-sectional data, which has led to large 
discrepancies in seroconversion and seroreversion rates 
[52]. Alternatively, linear regression models are used 
to provide information about the antibody acquisition 
[13, 21]. Helb et al. [13] and Yman et al. [12] estimated 
recent P. falciparum exposure at individual (longitudinal 
data) and population level (cross-sectional data). Studies 
based on longitudinal data mainly use approaches such 
as linear regression models [13, 20], generalized linear 
models (GLM) [64], or Ab-intensity models [12] to ana-
lyse Ab profiles.
A first criteria for selecting serological markers indica-
tive for recent infection, is that the marker can at least 
pick up current infection. Therefore, the Ab intensity 
in Plasmodium infected people was compared to non-
infected people. In agreement with results of previous 
studies, the present study shows that most Ab-responses 
(17/20) within each age group rise similarly by an infec-
tion. In contrast, in infected individuals Ab-responses to 
STARP.R, LSA1.41, GLURP, Pf.GLURP.R2 (among per-
sons between 6 and 50 years) and PvEBP (among children 
from 2 to 15  years) seem to be influenced by age. [65]. 
The differences among children can be explained based 
on the role of immunological maturity-status [6], as chil-
dren that acquire a malaria infection have the ability to 
boost their IgG titres, after which these Ab-titres decay 
again [66]. In this analysis it is important to take into con-
sideration that the group of PCR-negatives is very large, 
and that PCR negative persons might have been infected 
in the six months between sampling periods. Moreover, 
(See figure on previous page.) 
Fig. 4 Plasmodium vivax Ab profiles in relation to time since last infection compares to the systematically negative individuals over time. Each 
serological marker is analysed for Plasmodium vivax infections and three age groups (1–5, 6–15 and 16–50). Samples collected through longitudinal 
follow-up were aligned, starting with putting the malaria episode detected by PCR at time point zero. Points represent the different samples in 
which a linear regression is drawn through with the 95% confidence intervals. These outcomes were then compared to the group of individuals 
being systematically negative over time, to see if the Ab-levels follow a similar or different decay over time between the parasite positive and nega-
tive individuals
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for the PCR positive individuals, it is unknown when the 
infection was acquired.
In a next step, antibody decay rates (or half-lives) were 
estimated by using linear regression models that were fit 
on Ab-responses obtained from a cohort at different time 
points. In summary, the obtained results showed that the 
used serological markers could be divided in four groups 
with a wide variety of half-life estimates (Fig. 1; Table 3). 
Even though, limited information on the Abs persistence 
is available, some studies have previously estimated Ab 
half-lives [18, 20]. A study performed by Drakeley et al. 
[40] found a very long half-life of 49.8  years for Abs 
against Pv.MSP1.19, and Ondigo et  al. [67] found half-
lives from <1  year (3 Ags) to moderate (5–20  years for 
3 Ags) and very long (>40 years for 5 Ags) by means of 
the threshold approach. Wipasa et  al. [18] and Fowkes 
et  al. [20] found a clearance of approximately 7.6  years 
[18] and 0.8–7.6 years [20], respectively, through linear 
regression models for the same Abs. The estimated Ab-
clearance against merozoite Ags in the present study are 
best comparable with the latter results. However, these 
studies [18, 20] showed large ranges in 95% confidence 
intervals, which was also seen in the present study. The 
half-life estimates are in contrast with the underlying 
immunology showing the short period that merozoites 
Fig. 5 Forest plot representing the half-life per Ag in days. The half-lives based on the repeated measurement samples were estimated in days. 
A linear regression model was fitted on log-transformed MFI data taking into account age as factor. Estimated slopes and their 95% confidence 
intervals were used to obtain the half-life in days (t1/2 =
−ln(2)

). This forest plot represents the half-lives of each Ag ordered from the shortest to the 
longest half-life. The purple crosses represent an estimated half-life shorter than 7.5 months, the blue squares range from 8.5 months until 1 year, the 
red dots range from 13 until 19 months, and the green triangles represent an estimated half-life longer than 2 years. The error bars are the 95% con-
fidence intervals. A remarkable founding in this figure is that P. falciparum shows a clear difference between the short and long lived Ab-responses, 
while for the P. vivax only long lived Ab-responses are seen
Table 2 Amount of  cluster communities selected per  spe-
cies and per PCR prevalence level
Cluster communities were ordered per survey exhibiting high-, medium- 
and low-levels of PCR prevalence. This was performed on PCR data from 
all Plasmodium species (mono and mixed infections), P. falciparum (mono 
infections) and P. vivax (mono infections)
PCR prevalence P. falciparum P. vivax Plasmodium
High S2 13 14 19
S4 3 9 10
Medium S2 18 26 24
S4 21 23 24
Low S2 52 39 26
S4 61 44 31
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Fig. 6 Ab-responses to Plasmodium Ags in relation to the risk of malaria exposure in different villages. To examine the associations between the 
Ab-levels and the malaria exposure clusters of villages were divided into three groups (those with high—(7– >10%), medium—(1–3.5%), and 
low—(0– <1%) prevalence levels). In addition, because age plays a major role in the analysis of Ab-responses, the three age groups (2–5, 6–15 
and 16–50 years old) were included. Boxplots represent the medians, interquartile ranges and error bars show 95% confidence intervals. Circles 
represent outlier values. Ags showed to be statistical significant for model 3, a model with three groups of villages and age groups as a dependent 
variable (without interaction) taking into account Cluster and Survey as random effects. The figure only represents the Ags with the steepest decay 
(slope < −0.6)
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need to reinvade erythrocytes. This is the short timespan 
in which the Abs have direct contact with the merozoite 
surface proteins, as this is the moment they are actually 
visible in the blood circulation [68]. A short clearance of 
Abs against merozoite Ags was also shown by Kinyan-
jui et  al. [41] who estimated a clearance of 6–10  days 
and White et al. [66] that found a half-life of 7–72 days 
in children and 3–9  years for IgG Abs against AMA1, 
MSP1, MSP2 and CSP in infants, with a linear regres-
sion models. All these different outcomes suggest that 
using different model approaches (reversible catalytic 
conversion model and linear regression model) provide 
different outcomes, whereas with the linear regression 
models shorter half-lives were obtained. Moreover, large 
discrepancies in 95% confidence intervals were seen for 
some sporozoite related Ags as well. For these serologi-
cal markers lower MFI values were observed [data not 
shown], resulting in larger 95% confidence intervals of 
Ab half-lives. This is not surprising as small numbers of 
sporozoites are only briefly present in the blood circu-
lation to stimulate a sufficient production of sporozoite 
Abs, particularly, when situated in a region with low 
malaria transmission as the Mekong Subregion [17, 19]. 
Therefore, it has been previously suggested that the use 
of serological markers based on the sporozoite stage of 
malaria parasites might lead to an underestimation of 
the malaria endemicity in low transmission areas, while 
they possibly are more sensitive in hyper- and holo-
endemic settings [19].
Finally, the cross-sectional data were examined to 
investigate whether the serological markers were capable 
of picking up current differences in malaria prevalence. 
Overall, for a lower PCR prevalence in a group of villages, 
the observed MFI levels were also lower within all age 
groups. This trend was similar as what was observed by 
Ambrosino et al. [27], who observed a rise in malaria spe-
cific Ab-responses with an increasing malaria exposure 
per village [27].
Table 3 Three criteria to select the most promising antigens
Three criteria are used to select the most promising Ags for recent malaria infection. These criteria are based on: (1) the outcome of the estimated Ab-responses based 
on the differences in ln(MFI) between PCR positive and PCR negative individuals, (2) the assessed half-lives with the best Ab-responses of <7.5 months followed by 
Ab-responses between 8.5 months until 1 year and finally (3) the sensitivity to the level of malaria endemicity in communities
a Difference in ln(MFI) (ln-MFI PCR+ −ln-MFI PCR−); ++ (value > 1), + (value > 0.5),−(value < 0.5)
b Half-lives estimated via linear regression models; ++ (half-life < 7.5 months), + (half-life between 8.5 months–1 year),− (half-life > 1 year)
c Difference in intercept between PCR+ and PCR− for half-life estimation; ++ (intercept difference > 2), + (intercept difference between 1 and 2), − (intercept 
difference < 1)
d Sensitivity by endemicity estimated via linear regression models; ++ (IRR of PCR prev. decline with > 0.2, IRR increase by age with >4), + (IRR of PCR prev. decline 
with >0.1, IRR increase by age with >1)
Antigens Ags selection based on the three criteria
PCR+ vs PCR− valuesa Half‑lives (PCR+)b Differences in interceptc Sensitivity by endemicityd
P. falciparum CSP + + + +
Pf13 + + − +
STARP.R ++ + + +
SALSA2 + ++ + +
SR11.1 + + + +
LSA1.41 ++ + − ++
LSA1.J + + + ±
LSA3.RE ++ ++ ++ ++
Pf.MSP1.19 + − − −
GLURP ++ ++ ++ ++
Pf.GLURP.R2 ++ ++ ++ ++
P. vivax PvVK210.CSP − − − ±
PvVK247.CSP − − − ±
PvCSP − − − –
PvAMA1 − − − ±
PvEBP ++ − ++ ++
PvDBP − − − −
Pv.MSP1.19 − − − −
Vectors SALIV1 − − − −
SALIV2 − + − −
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Based on the three different criteria i.e. (1) sensitive to 
infection in individuals, (2) sensitive to the level of endemic-
ity in communities, and (3) a short half-life of IgG-Abs, the 
best serological markers (LSA3.RE, GLURP and Pf.GLURP.
R2) that reflect recent P. falciparum exposure were identi-
fied. Moreover, Ags, CSP, Pf13, STARP.R, SALSA2, SR11.1, 
LSA1.41 and LSA1.J also seemed to respond well to a lesser 
extent. Therefore, these Ags should not be ruled out for 
future research in different settings. PvEBP was selected as 
the better candidate for P. vivax surveillance.
Conclusion
Given the broad utility of serology, identifying serological 
markers for recent exposure seems a worthwhile invest-
ment [13]. In summary, it appears that for P. falciparum 
LSA3.RE, GLURP and Pf.GLURP.R2 are most likely to be 
reflective for recent exposure, whereas PvEBP is the only 
Ag from P. vivax that responds reasonably well, in spite 
of a half-life of more than 1  year. Therefore, it is essen-
tial to explore other Ags from P. vivax. The only available 
P. malariae antigen did not provide a good response. It is 
remarkable that the best reflective Ags are mainly liver- and 
blood stage Ags, whereas in contrast to high endemic areas 
sporozoite level Ags are not useful in this setting (low-
endemic). It is worth noting that all 20 Ags exhibit a direct 
link with the endemicity. In short, these Ags should cer-
tainly not be excluded for further in-depth analyses related 
to malaria control programmes. Another important aspect 
is that the use of Ab intensity data rather than dichotomiz-
ing the continuous Ab-titre data (positive vs negative) will 
lead to an improved approach for serological surveillance.
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Additional file 1. Raw data file. This file contains all raw data used for all 
analyses in this study.
Additional file 2. Example of Levey Jenning Charts plotted for the qual-
ity control of the immunoassay used for screening the field bloodspot 
samples. Data analysis started with a quality control on the ΔMFI-values of 
the 100% positive control pool samples (A). The dots represent each posi-
tive control sera sample in duplicate per plate. If these dots fell out of the 
−2SD and +2SD (red area), these plates were rejected and re-analysed. 
The same quality control was also performed on the percentage positivity 
(�MFILowpositivecontrol(Ag1)
�MFIHighpositivecontrol(Ag1)
 × 100%) calculated from the 50% positive control 
pool samples per Ag (B). Based on the outcome of both graphs, 30 plates 
were rejected and reanalysed.
Additional file 3. Multiplex assay on a dilution series of the control 
samples to confirm the linear range of the assay. The mean MFI values of 
the control samples (per dilution and per Ag) were plotted. Graphs were 
made species specific. The vertical black lines show the spot where the 
1:100, 1:400 and 1:1600 dilution is situated. Each of the Ags follow the 
linear range of the assay.
Additional file 4. Example of quantile regression model utilized on a MA-
plot to detect differences between the duplicate samples. The quantile 
regression model is a way to validate samples and their duplicates on 
consistency. The red and black dots represent the samples and duplicates 
of which the red dots represent the outliers. The dotted lines represent 
upper and lower fences (Q3 + 1.5IQR and Q1−1.5IQR), where Q1 is the 
lower 25th quantile and Q3 the upper 25th quantile and IQR = Q3 − Q1. 
The outer solid lines represent lower and upper bounds that classify the 
difference between the outliers and non-outliers.
Additional file 5. Example of a histogram in which the MFI values are 
plotted against different age categories. Given the trend between the 
various ages it has been observed that this might be an important factor 
that has to be taken into account. The boxplots represent the medians, 
interquartile ranges and error bars (95% confidence intervals) per age. 
Circles represent outlier values. In the first plot is performed on all 8,654 
samples, while the second plot has been performed on only the PCR posi-
tive samples. Looking at the trend it is clear that the MFI increase accord-
ing to the age. Samples above the age of 50 show variation in MFI levels 
and were therefore removed from the analysis. Therefore age groups from 
2–5, 6–15 and 16–50 years are chosen.
Additional file 6. Estimates of the half-life per serological marker. The 
half-lives based on the repeated measurement samples were estimated 
in days. A linear regression model was fitted on log-transformed MFI data 
taking into account age as factor. Estimated slopes and their 95% confi-




Additional file 7. Example of a Forest plot created to define the different 
levels of Clusters according to the PCR prevalence. To analyse Abs that 
pick up recent changes in malaria transmission, forest plots were created 
on the cluster prevalence data from survey 2 and 4 per Plasmodium spe-
cies (mono infections). Each cluster was examined twice, once for survey 
2 and once for survey 4. The dots represent the measured PCR prevalence 
(% proportion) for a certain village. The error bars represent the 95% 
confidence intervals. The villages are ordered from the village with the 
lowest to the village with the highest PCR % proportion. Different groups 
are automatically selected with a R-software [28] package. The group that 
showed a high overlap between two different levels of prevalence was 
removed for further analysis.
Additional file 8. Incidence rate ratios and p values estimated to indicate 
difference between the Ab intensity (ln(MFI)) and the levels of exposure 
per age group (6–5 and 16–50 years). Significant differences between the 
different levels of exposure (High-, Medium-, Low prevalence) were seen 
for all specific Ags (p<0.00025). The incidence rate ratios (IRR) confirm that 
the MFI value decline together with the PCR prevalence in the villages and 
rise with age. Incidence Rate Ratio that indicates for how much (if > 1) or 
less (if < 1) the covariates decline with PCR prevalence level or rise with an 
increasing age. This is performed in respect to the reference category and 
LCI and UCI representing the lower and upper 95% confidence intervals 
based on the total sample size of n = 6,499 individuals from 98 villages.
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